We describe the rare occurrence of a granulomatous pneumonitis seen in a patient following allogeneic bone marrow transplantation. Interestingly sarcoidosis was diagnosed in the marrow donor less than a year after donating his bone marrow. Bone Marrow Transplantation (2001) 28, 627-630. Keywords: alveolitis; extrinsic allergic; sarcoidosis; bone marrow transplantation; granuloma
lung zone. A subsequent CT scan revealed three small (less than 5 mm), ill-defined nodules in the right middle, right lower and the left lower lobes, respectively. The differential diagnosis included bronchiolitis obliterans organizing pneumonia (BOOP) vs recurrence of neoplastic disease. The patient was asymptomatic. A chest CT scan repeated 3 months later in August 1998 showed no change in the size or number of nodules. Serial chest radiographs thereafter were normal. The patient was managed conservatively with follow-up.
In December 1998, the patient presented with dry cough, low-grade fevers and dyspnea on exertion. A chest radiograph at this time showed new bilateral ill-defined basilar opacities. After oral azithromycin therapy, a repeat chest radiograph showed progressive increase in size of opacities with a diffuse ground-glass appearance. Examination showed the patient to be in mild respiratory distress with a room air oxygen saturation of 85%. She was febrile, tachycardic and appeared toxic. Chest auscultation revealed bibasilar inspiratory crackles. There was a petechial rash due to chronic GVHD over the lower extremities. A chest CT following admission showed multiple ill-defined centrilobular ground-glass opacities that were diffusely distributed but more confluent in the lower lobes (Figure 1a and b ). An open lung biopsy showed interstitial granulomatous inflammation with a histologic pattern suggestive of hypersensitivity pneumonitis ( Figure 2 ). Special stains for AFB and fungi were negative. The patient was started on methylprednisolone at 2 mg/kg/day and shortly after switched to oral prednisone 60 mg/day. Following the initiation of steroid therapy, there was a dramatic symptomatic improvement with a decrease in supplemental oxygen requirements. Chest radiographs showed marked improvement with a complete disappearance of opacities after 2 weeks. Cultures of both BAL and lung tissue were negative for AFB and fungi. The patient was extensively questioned about occupational, environmental, bird or hot-tub exposures, any drug use that might cause hypersensitivity pneumonitis; the patient however denied any specific exposures. A hypersensitivity pneumonitis panel done at follow-up (Aspergillus fumigatus, Aspergillus flavus, M. faeni, Theromoactinomyces vulgaris, T. candidus, T. sacchaci, pigeon serum) was negative. The patient continued to be on oral prednisone for severe GVHD affecting her skin over the next several months. A chest CT performed in July 1999 was normal.
Case report, donor
The patient's brother, a 36-year-old white male was apparently in good health until April 1998. Following a trip to Phoenix, AZ, he developed persistent cough, left lower chest pain, fever, fatigue and malaise. A chest radiograph showed bilateral hilar and mediastinal adenopathy. A chest CT scan showed pretracheal, right paratracheal and hilar adenopathy. Mediastinoscopy was performed and lymph node biopsies showed noncaseating granulomas. Acid fast and methanamine silver stains were negative. A diagnosis of sarcoidosis was rendered and the patient was treated with systemic steroids resulting in marked symptomatic improvement with resolution of cough and dyspnea.
Discussion
It is rare to encounter granulomatous inflammation in bone marrow transplant recipients. Granuloma formation requires the interaction of T helper cells and antigenpresenting macrophages in a manner that is HLA class II antigen-restricted. 1 Subsequent cytokine release by these two cell types leads to the collection of epithelioid cells, monocytes and lymphocytes that is termed a granuloma. The process of granuloma formation may be ineffective in transplantation due to the use of immunosuppression. Bone marrow transplantation results in the establishment of a donor-derived hematopoietic cell population and cell-mediated immunity in the recipient. Within 1-2 years following allogeneic transplantation, there is complete reconstitution of immune functions in the recipient. Despite the unclear role of thymic conditioning in adult bone marrow recipients, there appears to be normalization of CD4 + /CD8 + T cell ratios a year after transplantation. 2 In the first 3 months after bone marrow grafting, impaired cellular immunity is seen as measured by delayed-type hypersensitivity and in vitro proliferative responses to mitogens and antigens.
2 This is generally attributed to an increase in the absolute number of suppressor/cytotoxic lymphocytes and a decrease in absolute numbers of helper-inducer phenotype, thereby changing CD4 + /CD8 + ratios. Lower CD4 + /CD8 + ratios may reoccur or persist in recipients who develop chronic graft-versus-host disease.
2 Peripheral blood monocytes of donor origin have been demonstrated in bone marrow recipients by 41 days post grafting, whereas tissue-fixed donor macrophages in lung and liver are shown by 81 days.
2 Both increased and normal monocytic activity in the early postgrafting period have been noted. 2, 3 Reports of granulomatous diseases after bone marrow transplantation have included case reports of mycobacterial infection and one case of sarcoidosis that was presumably transferred from the donor to the recipient. 4, 5 Mycobacterial infections occur less frequently in bone marrow transplant patients as compared to other solid organ transplant recipients. 4 Reasons for the low occurrence include a relatively short period of immune ablation as compared to other patients with chronic immune suppression like solid organ recipients or AIDS patients. 4 Caseating granulomas due to tubercular and non-tubercular mycobacterial infections can occur within a year of transplantation of bone marrow transplantation. 4 Although invasive fungal pneumonias have been recognized with increasing frequency in BMT patients, reports of chronic granulomatous fungal infections are limited to case reports. 6 Among noninfectious causes, only one case of sarcoidosis has been described in a bone marrow recipient. 5 In that case granulomatous inflammation was demonstrated in the liver and the lungs of the recipient. 5 The steroid-responsive granulomatous pneumonitis seen in our patient raises interesting questions. A workup for infectious causes was negative and the recipient had no prior history of TB. The presence of sarcoidosis in the donor raised this as a possible cause for the granulomatous pneumonitis seen in the recipient. Our case bears many similarities to the previously reported case of apparent sarcoid transmission following bone marrow transplantation. 5 Both the recipients were in their fourth decade and had received treatment for non-Hodgkin's lymphoma prior to transplantation with a non-T celldepleted bone marrow harvest. 5 Both had HLA-identical donors that carried the HLA types A1 and B8, phenotypes that are positively associated with sarcoidosis in European populations. 7 Familial sarcoidosis is well described in sibling pairs. 8 Despite such similarities, neither the radiology nor the pulmonary pathology in our patient suggested sarcoidosis and there was no evidence of extrapulmonary involvement. Long-term follow-up in our recipient has shown no recurrence of disease, although it could have been suppressed by steroids used for GVHD. We are inclined to label our recipient with a diagnosis of non-infectious granulomatous pneumonitis, most likely hypersensitivity pneumonitis, although there was no history of any specific exposure or supportive ancillary laboratory evidence. This is not unusual in the diagnosis of hypersensitivity pneumonitis (HP), where cases showing typical histology of HP in the absence of exposure history have been described. 9 The conditioning regimen and combination chemotherapy that patients with hematologic malignancies undergoing BMT receive predisposes them to pulmonary complications. These usually take the form of interstitial pneumonitis, idiopathic pneumonia syndrome, diffuse alveolar hemorrhage, BOOP, and bronchiolitis obliterans secondary to chronic GVHD. 10 Our bone marrow recipient developed a pulmonary manifestation that appeared histologically and clinically distinct from theabove-mentioned pulmonary complications seen after BMT. 10 Steroid-responsive drug-related pulmonary reactions have also been reported in patients with breast cancer and lymphoma undergoing autologous BMT, although there are no reports of any granulomatous pathology seen as a result of drug reactions in patients undergoing BMT. Our patient received cytotoxic therapy with cyclophosphamide, procarbazine and cytosine arabinoside, medications that have been associated with cellular hypersensitivity Bone Marrow Transplantation reactions. 11 These medications are unlikely to be the cause of the pneumonitis seen in our recipient as they were administered more than 18 months before and have not been reported to cause a granulomatous reaction, as was seen in our patient. 11 One case of cyclosporineinduced hypersensitivity pneumonitis in a patient with Crohn's colitis has been reported so far. 12 This patient however was not rechallenged with the drug and exposure history and ancillary testing for HP is not mentioned in this case report.
12 GVHD-related pulmonary injury can also be considered a possibility in view of the concomitant cutaneous GVHD seen in our patient. However, the histological pattern of pulmonary involvement seen in our patient does not fall into the spectrum of pulmonary GVHD reactions reported in BMT recipients. 13 Both sarcoidosis and HP present with immune-granulomata in the lung that are steroid-responsive. Even though a CD8 T cell preponderance in the BAL fluid is generally accepted in cases of HP, there appear to be variable and conflicting results in reports regarding this finding in studies on BAL cytologies.
14 A dominant Th1 cytokine profile appears to underlie the expression of granulomatous responses in both sarcoidosis and hypersensitivity pneumonitis. 14, 15 More importantly, there is need for appropriate T cell-monocyte/macrophage interactions in response to undefined (sarcoidosis) or defined (HP) antigens resulting in production of specific cytokines for the ultimate expression of these illnesses.
14 Our case raises important questions with regard to individual susceptibility to these non-infectious pulmonary granulomatous illnesses. Does the transfer of appropriate T cell-monocyte subsets, as occurs following bone marrow transplantation, confer a propensity to the development of non-infectious granulomatous illnesses? More importantly, is there a need for a particular HLA type as has been noted in sarcoidosis for initiating processes that lead to granuloma formation?
